Earnings History Data for Aligos Therapeutics, Inc. (ALGS) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 06-11-2024 | AH | ALGS | Aligos Therapeutics, Inc. | 30.30 | -3.07 | -2.15 | -10.25 | Aligos Therapeutics EPS of -$3.07 misses by $1.75 [11/6/2024 5:04 PM] |
9.88 | 0.53 (5.70%) |
9.30 | -0.05 (-0.53%) |
6.76 - 30.00 | 166,146 | 220,000 | 1,323 | ||
|
||||||||||||||||||
| 06-08-2024 | AH | ALGS | Aligos Therapeutics, Inc. | 41.40 | 0.03 | -0.16 | -0.43 | Aligos Therapeutics GAAP EPS of $0.03 beats by $0.19 [8/6/2024 4:52 PM] |
0.55 | 0.10 (23.04%) |
0.48 | 0.03 (7.36%) |
0.35 - 1.20 | 1,345,014 | 290,000 | 101,371 | ||
| 07-05-2024 | AH | ALGS | Aligos Therapeutics | 64.00 | -0.22 | -0.19 | 0.00 | Aligos Therapeutics reports Q1 results [5/8/2024 10:42 AM] |
0.80 | 0.01 (1.27%) |
0.81 | 0.02 (2.53%) |
0.54 - 1.34 | 161,878 | 210,000 | 405 | ||
| 12-03-2024 | AH | ALGS | Aligos Therapeutics, Inc. | 62.95 | -0.22 | -0.27 | -0.51 | Aligos Therapeutics GAAP EPS of -$0.22 beats by $0.05, revenue of $2.68M beats by $1.08M [3/12/2024 4:16 PM] |
0.8750 | 0.0 (0.57%) |
0.87 | 0.0 (0.00%) |
0.54 - 1.51 | 1,277,537 | 460,000 | 3,513 | ||
| 02-11-2023 | AH | ALGS | Aligos Therapeutics, Inc. | 26.10 | -0.41 | -0.48 | -0.44 | Aligos Therapeutics GAAP EPS of -$0.41 [11/2/2023 4:51 PM] |
0.7603 | 0.01 (1.37%) |
0.73 | -0.02 (-2.80%) |
0.54 - 2.41 | 86,409 | 220,000 | 12,039 | ||
| 03-08-2023 | AH | ALGS | Aligos Therapeutics, Inc. | 37.79 | -0.43 | -0.50 | -0.47 | Aligos Therapeutics GAAP EPS of -$0.43 beats by $0.06, revenue of $2.59M [8/3/2023 5:59 PM] |
0.8850 | 0.0 (-0.55%) |
0.91 | 0.02 (2.25%) |
0.84 - 2.41 | 23,495 | 90,000 | 204 | ||
| 04-05-2023 | AH | 4:05 PM ET (May 4) |
ALGS | Aligos Therapeutics, Inc. | 51.96 | -0.53 | -0.47 | -0.84 | Aligos Therapeutics GAAP EPS of -$0.53 misses by $0.05, revenue of $2.58M [5/4/2023 5:25 PM] |
1.24 | -0.12 (-8.82%) |
1.37 | 0.01 (0.74%) |
0.84 - 2.41 | 111,402 | 70,000 | 3,006 | |
| 09-03-2023 | AH | 4:05 PM ET (Mar 9) |
ALGS | Aligos Therapeutics, Inc. | 70.65 | -0.51 | -0.49 | -0.89 | Aligos Therapeutics GAAP EPS of -$0.51 misses by $0.02, revenue of $3.54M beats by $1.39M [3/9/2023 4:46 PM] |
1.30 | -0.06 (-4.41%) |
1.36 | 0.0 (0.00%) |
0.84 - 2.99 | 157,113 | 80,000 | 100 | |
| 02-11-2022 | AH | 4:05 PM ET (Nov 2) |
ALGS | Aligos Therapeutics, Inc. | 44.95 | -0.44 | -0.57 | -0.78 | Aligos Therapeutics GAAP EPS of -$0.44 beats by $0.14, revenue of $4.12M beats by $3.37M [11/2/2022 4:51 PM] |
1.04 | -0.03 (-2.80%) |
1.12 | 0.05 (4.67%) |
0.98 - 17.97 | 20,134 | 40,000 | 500 | |
| 04-08-2022 | AH | 4:05 PM ET (Aug 4) |
ALGS | Aligos Therapeutics, Inc. | 61.05 | -0.47 | -0.65 | -0.79 | Aligos Therapeutics GAAP EPS of -$0.47 beats by $0.18, revenue of $3.69M [8/4/2022 4:52 PM] |
1.50 | 0.11 (7.91%) |
1.45 | 0.06 (4.32%) |
1.03 - 17.97 | 120,414 | 80,000 | 860 | |
| 04-05-2022 | AH | 4:05 PM ET (May 4) |
ALGS | Aligos Therapeutics | 50.00 | -0.84 | -0.66 | 0.00 | Aligos Therapeutics GAAP EPS of -$0.84, revenue of $2.57M [5/4/2022 5:20 PM] |
1.09 | -0.15 (-12.09%) |
1.15 | -0.09 (-7.26%) |
1.07 - 34.31 | 371,412 | 210,000 | 57,207 | |
|
||||||||||||||||||
| 10-03-2022 | AH | 4:05 PM ET (Mar 10) |
ALGS | Aligos Therapeutics, Inc. | 108.67 | -0.89 | -0.82 | -1.09 | Aligos Therapeutics GAAP EPS of -$0.89 misses by $0.06 [3/10/2022 4:31 PM] |
2.59 | 0.14 (5.71%) |
2.57 | 0.12 (4.90%) |
2.11 - 34.31 | 229,598 | 330,000 | 17,130 | |
| 04-11-2021 | AH | 4:05 PM ET (Nov 4) |
ALGS | Aligos Therapeutics, Inc. | 682.59 | -0.78 | -0.83 | 0.00 | Aligos Therapeutics EPS beats by $0.03 [11/4/2021 5:23 PM] |
16.85 | 0.89 (5.58%) |
15.75 | 0.0 (0.00%) |
13.30 - 37.51 | 139,551 | 170,000 | 3,892 | |
| 05-08-2021 | AH | 4:05 PM ET (Aug 5) |
ALGS | Aligos Therapeutics, Inc. | 662.14 | -0.79 | -0.81 | 0.00 | Aligos Therapeutics EPS beats by $0.02 [8/5/2021 4:44 PM] |
15.93 | -0.30 (-1.85%) |
16.23 | 0.0 (0.00%) |
12.82 - 37.51 | 210,543 | 290,000 | 471 | |
| 10-05-2021 | AH | 4:05 PM ET (May 10) |
ALGS | Aligos Therapeutics, Inc. | 1,030 | -0.74 | -0.90 | 0.00 | Aligos Therapeutics EPS beats by $0.16 [5/10/2021 4:57 PM] |
26.37 | 1.34 (5.35%) |
0.0 | 0.0 (0.00%) |
12.82 - 37.51 | 66,126 | 60,000 | 0 | |